|
|
|
| Pathogenesis of ISNA and it′s research progess of the prevention and control of traditional Chinese and western medicine |
| LI Danyun1 WANG He2 SI Chunying2 LUO Minghua2 CHEN Yushan2 GUAN Huaimin2 |
1.The Graduate School, He'nan University of Chinese Medicine, He'nan Province, Zhengzhou 450000, China;
2.Heart Center, First Affiliated Hospital of He'nan University of Chinese Medicine, He'nan Province, Zhengzhou 450000, China |
|
|
|
Abstract Percutaneous coronary intervention has become the important means on the therapy of coronary heart disease. But, the current clinical problems solved are postoperative restenosis and late stent thrombos is which can cause serious adverse cardiovascular events. Studies have found that in-stent neoatherosclosis is an important reason of ISR and LST. For the prevention and treatment of ISNA is the entry point to improve the long-term effect of coronary stent at present. In this paper, the pathogenesis of neonatal atherosclerosis and the prevention and treatment of Chinese and western medicine were discussed.
|
|
|
|
|
|
[1] Wong DT，Soh SY，Malaiapan Y. In-stent thrombosis due to neoatherosclerosis：insight from optical coherence tomography [J]. J Invasive Cardiol，2013，25（6）：304.
[2] Tian F，Chen Y，Liu H，et al. Assessment of characteristics of neointimal hyperplasia after drug-eluting stent implantation in patients with diabetes mellitus：an optical coherence tomography analysis [J]. Cardiology，2014，128（1）：34-40.
[3] 陈玉善，张金盈，关怀敏，等.应用光学相干断层成像评价药物洗脱支架术后再发急性冠脉综合征患者的原因[J].医药论坛杂志 ，2013，34（8）：13-15，18.
[4] Nakazawa G，Otsuka F，Nakano M，et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents [J]. J Am Coll Cardiol，2011，57（11）：1314-1322.
[5] Park SJ，Kang SJ，Virmani R，et al. In-stent neoatherosclerosis：a final common pathway of late stent failure [J]. J Am Coll Cardiol，2012，59（23）：2051-2057.
[6] Kang SJ，Mintz GS，Akasaka T，et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation [J]. Circulation，2011，123（25）：2954-2963.
[7] Touchard AG，Schwartz RS. Preclinical restenosis models：challenges and successes [J]. Toxicol Pathol，2006，34（1）：11-18.
[8] Taniwaki M，Windecker S，Zaugg S，et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression：a long-term angiographic and optical coherence tomography cohort study [J]. Eur Heart J. 2015，36（32）：2167-2176.
[9] 李承辉.血府逐瘀汤对冠心病行介入治疗术后患者心绞痛的影响[J].世界最新医学信息文摘，2015，17（A3）：199-204.
[10] 李松，张敏州，邹旭，等.辨证分型治疗对冠心病介人术后患者血浆FIB及血脂的影响[J].南京中医药大学学报，2005，21（2）：89-92.
[11] 杨华伟.加味温胆汤对冠心病PCI术后左室收缩功能的影响[J].中国当代医药，2010，17（22）：128-131.
[12] Giacoppo D，Gargiulo G. Treatment strategies for coronary in-stent restnosis：systematic review and heerarchical Bayesian network meta-analysis of 24randomised trials and 4880 patients [J]. BMJ，2015，351.
[13] 狄佳.活血化瘀法对冠状动脉小血管长病变支架术后再狭窄的影响研究[C]//中华医学会、中华医学会急诊医学分会.中华医学会急诊医学分会第十六次全国急诊医学学术年会论文集，2013：1.
[14] 付达，郝晓丹，刘真.从瘀毒理论探讨冠状动脉支架内再狭窄的预防[J].中医学报，2017，32（2）：257-259.
[15] 徐惠梅，海锦歌.支架内再狭窄的中医药研究进展[J].黑龙江中医药，2013，43（4）：8-9.
[16] 代国方，张保珠，王菲.通脉方防治冠脉支架植入术后气虚血瘀型病人再狭窄的临床研[J].中西医结合心脑血管病杂志，2017，15（2）：136-142.
[17] 邹国辉，黄小燕，唐娜娜，等.解毒活血方对经皮冠状动脉介入术后患者NF-κB、IL-1β、TNF-α变化及支架内再狭窄的影响[J].广州中医药大学学报，2017，34（1）：1-5.
[18] Chen KJ，Shi DZ，Xu H，et al，XS0601 reduces the incidence of restenosis ：a prospective study of 335 patients undergoing percutaneous coronary intervention in China [J]. Chin Med J，2006，119（1）：6-13.
[19] 朱烨，唐元升.通心络胶囊对血管内皮损伤的保护作用[J].山东医药，2011，51（17）：113-114.
[20] 李振宇，张洁玉，耿乃志，等.丹蒌片治疗痰瘀互结型心绞痛的疗效观察[J].中国临床保健杂志，2016，19（4）：412-416.
[21] 胡运琴.益气活血祛痰法防治冠状动脉支架术后再狭窄21例[J].河南中医，2010，30（7）：675-676. |
|
|
|
